Menzies 2008.
Study characteristics | |||
Patient sampling |
Study design: case series? Data collection: retrospective image selection/prospective interpretation Period of data collection: NR Country: multicentre |
||
Patient characteristics and setting |
Inclusion criteria: dermoscopic amelanotic (with no melanin pigmentation) or hypomelanotic (a melanin pigmentation area of < 25% of the total surface area or slightly pigmented but with no dark brown, deep blue, or black pigmentation) lesions. All melanomas included, and a random selection of melanocytic and non‐melanocytic lesions on a non‐melanoma to melanoma ratio of 3:1 Setting: multicentre Prior testing: NR Setting for prior testing: NR Exclusion criteria: lesions were excluded because of poor image quality or because they did not fit within any of the defined pigmentation categories Sample size (participants): NR Sample size (lesions): 497 Participant characteristics: NR Lesion characteristics: NR |
||
Index tests |
Dermoscopy: 7PCL; Menzies; 3PCL (new algorithm for distinguishing melanoma from non‐melanoma and any malignant from benign lesions was also developed on 80% of sample and tested on 20% but numbers disease‐positive and ‐negative for the test set were NR to allow 2x2 to be estimated.) Method of diagnosis: image‐based Prior test data: NR Diagnostic threshold: ≥ 3; Menzies standard threshold; ≥ 2 Diagnosis based on: single observer Observer qualifications: dermatologist (assumed) (n = 12); clinicians experienced in dermoscopic evaluation scored 99 individual morphological features in approximately equal sample sizes Experience in practice: NR Experience with dermoscopy: high |
||
Target condition and reference standard(s) |
Reference standard: histology and follow‐up (numbers NR; some naevi included that showed no changes following consecutive digital monitoring) Target condition (final diagnoses) Invasive melanoma 91; melanoma in situ 14; BCC 126; cSCC 4 Benign naevi 159; SN 11; SK 22; DF 17; BD 7; keratoacanthoma 1; AK 8; other 37 |
||
Flow and timing |
Excluded participants: none reported Time interval to reference test: NR |
||
Comparative | |||
Notes | ‐ | ||
Methodological quality | |||
Item | Authors' judgement | Risk of bias | Applicability concerns |
DOMAIN 1: Patient Selection | |||
Was a consecutive or random sample of patients enrolled? | Yes | ||
Was a case‐control design avoided? | Yes | ||
Did the study avoid inappropriate exclusions? | No | ||
Are the included patients and chosen study setting appropriate? | No | ||
Did the study avoid including participants with multiple lesions? | Unclear | ||
High | High | ||
DOMAIN 2: Index Test Dermoscopy ‐ image‐based | |||
Were the index test results interpreted without knowledge of the results of the reference standard? | Yes | ||
If a threshold was used, was it pre‐specified? | Yes | ||
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? | No | ||
Was the test applied and interpreted in a clinically applicable manner? | No | ||
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? | Yes | ||
Was the test interpretation carried out by an experienced examiner? | Yes | ||
Low | High | ||
DOMAIN 3: Reference Standard | |||
Is the reference standards likely to correctly classify the target condition? | Unclear | ||
Were the reference standard results interpreted without knowledge of the results of the index tests? | Unclear | ||
Expert opinion (with no histological confirmation) was not used as a reference standard | Yes | ||
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? | Unclear | ||
Unclear | Unclear | ||
DOMAIN 4: Flow and Timing | |||
Was there an appropriate interval between index test and reference standard? | Unclear | ||
Did all patients receive the same reference standard? | No | ||
Were all patients included in the analysis? | Yes | ||
If the reference standard includes clinical follow‐up of borderline/benign appearing lesions, was there a minimum follow‐up following application of index test(s) of at least: 3 months for melanoma or cSCC or 6 months for BCC? | |||
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less? | |||
High |